Prostaglandin E2 measurements: their value in the early diagnosis of heterotopic ossification in spinal cord injury patients.
Details
Serval ID
serval:BIB_559695D8D285
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Prostaglandin E2 measurements: their value in the early diagnosis of heterotopic ossification in spinal cord injury patients.
Journal
Archives of Physical Medicine and Rehabilitation
ISSN
0003-9993 (Print)
ISSN-L
0003-9993
Publication state
Published
Issued date
1997
Volume
78
Number
7
Pages
687-691
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Abstract
OBJECTIVE: To look for a possible relation between the occurrence of heterotopic ossification (HO) and the modifications of the 24-hour prostaglandin E2 (PGE2) urinary excretion.
DESIGN: A 5-year prospective study to determine the 24-hour urinary excretion of PGE2 by radioimmunoassay with specific antisera not cross-reacting with TXA2, TXB2, 15-keto-PGE2 alpha, PGI2, 6-keto-PGF1 alpha.
SETTING: The laboratory of a division of endocrinology and diabetology of a university hospital.
PATIENTS: Of 262 acute spinal cord injury patients screened, 44 were eligible for the study.
INTERVENTIONS: Serial diagnostic quantitative bone scannings with technetium 99m Tc methylene diphosphate (99mTc-MDP) and therapeutic assessment of radiotherapy and indomethacin.
MEAN OUTCOME MEASURE: Hypothetical increase of PGE2 before and during HO formation.
RESULTS: Of 44 patients, 8 developed an HO (18.8%) with concomitant marked increase of the PGE2 excretion for as long as the HO had not reached maturity. The results of the radiotherapy were inconclusive. Indomethacin was shown to be efficacious in holding back or slowing down the HO evolution.
CONCLUSIONS: Measurement of the 24-hour PGE2 urinary excretion appears to be a valuable indicator in the early diagnosis of HO. Indomethacin should be considered as an alternative to other existing therapies.
DESIGN: A 5-year prospective study to determine the 24-hour urinary excretion of PGE2 by radioimmunoassay with specific antisera not cross-reacting with TXA2, TXB2, 15-keto-PGE2 alpha, PGI2, 6-keto-PGF1 alpha.
SETTING: The laboratory of a division of endocrinology and diabetology of a university hospital.
PATIENTS: Of 262 acute spinal cord injury patients screened, 44 were eligible for the study.
INTERVENTIONS: Serial diagnostic quantitative bone scannings with technetium 99m Tc methylene diphosphate (99mTc-MDP) and therapeutic assessment of radiotherapy and indomethacin.
MEAN OUTCOME MEASURE: Hypothetical increase of PGE2 before and during HO formation.
RESULTS: Of 44 patients, 8 developed an HO (18.8%) with concomitant marked increase of the PGE2 excretion for as long as the HO had not reached maturity. The results of the radiotherapy were inconclusive. Indomethacin was shown to be efficacious in holding back or slowing down the HO evolution.
CONCLUSIONS: Measurement of the 24-hour PGE2 urinary excretion appears to be a valuable indicator in the early diagnosis of HO. Indomethacin should be considered as an alternative to other existing therapies.
Keywords
Acute Disease, Adult, Anti-Inflammatory Agents, Non-Steroidal/therapeutic use, Chemotherapy, Adjuvant, Dinoprostone/urine, Female, Humans, Indomethacin/therapeutic use, Male, Middle Aged, Ossification, Heterotopic/etiology, Ossification, Heterotopic/radionuclide imaging, Prospective Studies, Radioimmunoassay, Reproducibility of Results, Spinal Cord Injuries/complications
Pubmed
Web of science
Create date
05/11/2014 13:12
Last modification date
20/08/2019 15:10
Usage data
